These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34631752)

  • 1. Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19.
    Hashimoto S; Yoshizaki K; Uno K; Kitajima H; Arai T; Tamura Y; Morishita H; Matsuoka H; Han Y; Minamoto S; Hirashima T; Yamada T; Kashiwa Y; Kameda M; Yamaguchi S; Tsuchihashi Y; Iwahashi M; Nakayama E; Shioda T; Nagai T; Tanaka T
    Front Med (Lausanne); 2021; 8():734838. PubMed ID: 34631752
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
    Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
    J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.
    Kooistra EJ; van Berkel M; van Kempen NF; van Latum CRM; Bruse N; Frenzel T; van den Berg MJW; Schouten JA; Kox M; Pickkers P
    Crit Care; 2021 Aug; 25(1):281. PubMed ID: 34353339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
    Camou F; Issa N; Hessamfar M; Guisset O; Mourissoux G; Pedeboscq S; Minot A; Bonnet F
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.
    McKenzie MG; Lee YM; Mathew J; Anderson M; Vo AT; Akinyele S; Narayanan M
    J Pharm Pract; 2022 Aug; 35(4):587-592. PubMed ID: 33736526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
    Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
    Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
    Bhandari S; Rankawat G; Singh A
    Indian J Crit Care Med; 2021 Mar; 25(3):260-266. PubMed ID: 33790504
    [No Abstract]   [Full Text] [Related]  

  • 12. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.
    Lim PC; Wong KL; Rajah R; Chong MF; Chow TS; Subramaniam S; Lee CY
    Daru; 2022 Jun; 30(1):211-228. PubMed ID: 35084705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
    Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
    J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.
    Huang E; Isonaka S; Yang H; Salce E; Rosales E; Jordan SC
    Int J Infect Dis; 2021 Apr; 105():245-251. PubMed ID: 33609773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.
    Meleveedu KS; Miskovsky J; Meharg J; Abdelrahman A; Tandon R; Moody AE; Dasilva P; Masse G; LaPorte J; Saied Calvino A; Allen G; El-Bizri R; Roberts T; Armenio V; Katz SC
    Cytokine X; 2020 Dec; 2(4):100035. PubMed ID: 32895645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.
    Gholinataj Jelodar M; Rafieian S; Saghafi F; Hadad Zedegan N; Birjandi B; Rafieian S; Allah Dini A; Dehghanpour H; Khalaj F; Zare S; Dehghan Chenari H; Hajimaghsoudi M; Mojtaba Sohrevardi S; Mirzaei S; Jamialahmadi T; Atkin SL; Sahebkar A
    Int Immunopharmacol; 2023 Feb; 115():109623. PubMed ID: 36577157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
    Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
    Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.